One study reported that enzalutamide (an AR receptor antagonist)-induced FDHT uptake changes in metastatic lesions could be considered a surrogate marker for response of prostate cancer metastases with AR overexpression to ADT [56]. The gene discussed is AR; the disease is Familial prostate cancer.